GSK plc (GSK) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Total Cash From Operating Activities Chart for GSK plc
GSK plc (GSK) operating cash flow for FY2025 was GBP 7.3B, a 11.4% change from FY2024. GSK plc's operating cash flow grew from GBP 615.0M in 1990 to GBP 7.3B in 2025 (1087.5% over 35 years). Operating cash flow compound annual growth rate: 5-year CAGR of -2.9%, 10-year CAGR of 11.0%, 20-year CAGR of 1.3%.
Total Cash From Operating Activities (British Pounds)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- £74.16B
- Implied Share Price
- £18.52
- Enterprise Value
- £87.93B
- Revenue (TTM)
- £33.20B
- EBITDA
- £10.82B
- Profit Margin
- 14.52%
- Trailing P/E
- 15.69
- Forward P/E
- 19.76
- Price/Book (MRQ)
- 4.13
- Price/Sales (TTM)
- 2.23
- EV/EBITDA
- 9.09
- EV/Revenue
- 2.65
- Dividend Yield
- 3.74%
- Book Value
- £4.40
- Free Cash Flow (FY2025)
- £5.96B
- Free Cash Flow Yield
- 8.03%
Snapshot as of 18th August 2026 — not point-in-time controlled, may lag the live market by a few days.